32results about How to "Good specific binding ability" patented technology

The invention relates to a hybridoma cell strain and a secreted monoclonal antibody thereof; the antibody can be specifically combined with a human IgM, and can be used for in vitro detection of the human IgM, and particularly suitable for early diagnosis of rubella virus infection. The invention further relates to a kit comprising the hybridoma cell strain or the monoclonal antibody.

The invention relates to an anti-cryptococcal capsular polysaccharide hybridoma cell strain and an anti-cryptococcal capsular polysaccharide monoclonal antibody secreted thereof. The antibody can be specifically bound to cryptococcal capsular polysaccharide and can be used for in vitro detection of cryptococcal infection. The antibody titer is up to more than one million, and the antibody has excellent affinity and good specific binding capability. The detection limit of a colloidal gold-labeled immunodiagnostic reagent developed with the antibody as the raw material is 0.5 ng / ml, and the antibody has excellent performance in sensitivity, specificity, stability and all other aspects.

The invention relates to a hybridoma cell strain and a monoclonal antibody secreted by the same. The antibody can be specifically bound with human IgG. The invention further relates to a kit comprising the hybridoma cell strain or the monoclonal antibody. The monoclonal antibody disclosed by the invention shows good performances in the aspects of antibody purity, repeatability, antibody valence and stability.

The invention relates to a hybridoma cell strain and a monoclonal antibody secreted by the same. The antibody can specifically bind with human IgG. The invention further relates a kit comprising the hybridoma cell strain or the monoclonal antibody. The monoclonal antibody is good in antibody purity, repeatability, antibody valence and stability.

The invention relates to a hybridoma cell strain and a monoclonal antibody secreted by the hybridoma cell strain. The antibody can achieve specific binding to human IgM and is applicable to in vitro detection of human IgM; and the antibody is especially suitable for early diagnosis of hepatitis a virus infection. The invention also relates to a kit comprising the hybridoma cell strain or the monoclonal antibody.

The invention relates to a hybridoma cell strain and a monoclonal antibody secreted by the hybridoma cell strain. The antibody can be specifically bound with human IgM, and can be used for in-vitro detection of the human IgM, and especially suitable for the early diagnosis of cytomegalovirus infection. The invention further relates to a kit containing the hybridoma cell strains or the monoclonal antibodies.

The invention discloses an anti-toxoplasma gondii IgG monoclonal antibody, a hybridoma cell strain, a toxoplasma gondii detection kit and application thereof. The hybridoma cell strain is preserved inthe China Center for Type Culture Collection, and the preservation number is CCTCC NO: C2018175. The monoclonal antibody which is secreted by the hybridoma cell disclosed by the invention is specifically bound with an anti-toxoplasma gondii IgG antibody. The hybridoma cell strain and the monoclonal antibody which are provided by the invention have the advantages of high specificity, high sensitivity, good stability and no cross reaction, and can be applied to the kit of the IgG antibody for detecting toxoplasma gondii infection.

The invention relates to a hybridoma cell strain and a monoclonal antibody secreted by the same, and further relates to a kit comprising the hybridoma cell strain or the monoclonal antibody. The monoclonal antibody can specifically bind with human IgM, can be used for invitro detecting of the human IgM and is especially suitable for being used for early diagnosis of herpes simplex virus infection.

The invention relates to a hybridoma cell strain and a monoclonal antibody secreted by the hybridoma cell strain. The antibody can realize the specific combination with the human IgM, can be used forhuman IgM in-vitro detection, and is particularly suitable for being used for early diagnosis of hepatitis B virus. The invention also comprises a kit comprising the hybridoma cell strain or the monoclonal antibody.

The invention relates to a specific polypeptide targeted binding to lymphoma cell lines and application thereof, and belongs to the field of biomedicine. The specific polypeptide is based on a phage display technology in vitro, in vitro panning and obtaining a specific polypeptide TUZG12 capable of targeted binding the lymphoma cell lines. In vitro cell uptake and distribution experiments prove that the polypeptide has targeted binding activities to the lymphoma cell lines. According to the specific polypeptide targeted binding to the lymphoma cell lines, the results of in vitro cell viabilityexperiments show that the pro-apoptotic peptide DKK can enhance the inhibitory effect of DKK on proliferation of lymphoma cells to a certain extent after coupling TUZG12 polypeptide. The polypeptidescreened in the invention has good targeted binding activities to multiple lymphoma cell lines, and can enhance the killing effect of cytotoxic polypeptides on target tumor cells, and has an importantapplication value in the clinical diagnosis and treatment of lymphoma.

The invention relates to an anti-cryptococcus capsular polysaccharide hybridoma cell strain and an anti-cryptococcus capsular polysaccharide monoclonal antibody secreted thereby. The antibody can be specifically bound to cryptococcal capsular polysaccharide and can be used for in vitro detection of cryptococcal infection. The antibody titer is up to more than one million, and the antibody has excellent affinity and has good specific binding capability. The detection limit of a colloidal gold-labeled immunodiagnostic reagent developed by using the antibody is 0.5 ng / ml, and the colloidal gold-labeled immunodiagnostic reagent has better performance in aspects of sensitivity, specificity, stability and antibody.

The invention relates to a hybridoma cell stain and a monoclonal antibody secreted by the hybridoma cell strain, and the antibody can specifically bind to human IgG. The invention also relates to a kit comprising the hybridoma cell strain or monoclonal antibody. The monoclonal antibody of the invention exhibits good performance in the aspects of antibody purity, repeatability, antibody titer and stability.

The present invention relates to a hybridoma cell strain and a monoclonal antibody secreted thereof, the monoclonal antibody can specifically bind to human IgM and can be used for in vitro detection of the human IgM, and is particularly suitable for early diagnosis of parainfluenza virus infection. The invention also relates to a kit comprising the hybridoma cell strain or the monoclonal antibody.

The invention relates to a hybridoma cell strain and a monoclonal antibody secreted by the hybridoma cell strain. The antibody can be specifically bound with human IgM, and can be used for in-vitro detection of the human IgM, and especially suitable for the early diagnosis of hepatitis E virus infection. The invention further relates to a kit containing the hybridoma cell strains or the monoclonalantibodies.

The invention relates to a specific polypeptide in targeted binding with lymph cancer cells and application thereof and belongs to the field of biological medicine. The amino acid sequence of polypeptide D-REVTUZG12 is RMLSGHGANPHM. The polypeptide D-REVTUZG12 consists of D-type amino acids. It is proved through in-vitro cellular uptake and distribution experiment that the polypeptide D-REVTUZG12with a D-type inverted sequence structure has the targeted binding activity on lymphoma cell lines Jeko-1, P815, Raji and Su-4, but has no targeted binding activity on Romas and Granta-519 lymphoma cell lines and normal lymphocytes of human. The polypeptide has good targeted binding activity on multiple lymphoma cell lines and has the important application prospect in clinical diagnosis and targeted treatment of lymphoma.

The invention belongs to the technical field of biology, and particularly relates to a Rasal2 123-site phosphorylated antibody, a preparation method thereof, an ELISA detection kit for detecting Rasal2 123-site phosphorylation and a detection method. The preparation method comprises the following steps: synthesizing an antigen peptide of which S123 site is phosphorylated; coupling the antigen peptide with hemocyanin to obtain an immunizing antigen, then immunizing an animal by using the antigen and collecting antiserum; and identifying and purifying the antiserum to obtain the Rasal2 123-site phosphorylation specific antibody. The ELISA detection kit is obtained by coating an ELISA plate with the Rasal2 123-site phosphorylation specific antibody and assisting with other detection materials. The ELISA detection kit can be used for identifying a 123-th phosphorylation content of Rasal2 protein in a tissue sample, and is simple and convenient to operate, high in specificity, high in sensitivity and easy to standardize.

The invention belongs to the field of molecular biology, in particular to a coumarin derivative that specifically recognizes and distinguishes DNA and RNA, a preparation method and application thereof. The coumarin derivative has the structural formula of probe 1 or the structural formula of probe 2 . The probe in the invention is simple to synthesize, has high yield, can specifically recognize and distinguish DNA and RNA, and has good specificity and high sensitivity. This provides a new idea and method for the development of small molecule fluorescent probes for the specific distinction of DNA and RNA.

The present invention relates to a hybridoma cell strain and a monoclonal antibody secreted thereof, the monoclonal antibody can specifically bind to human IgM and can be used for in vitro detection of the human IgM, and is particularly suitable for early diagnosis of mumps virus infection. The invention also relates to a kit comprising the hybridoma cell strain or the monoclonal antibody.

The present invention provides an anti-TIGIT monoclonal antibody and application thereof, the anti-TIGIT monoclonal antibody comprises a heavy chain variable region and a light chain variable region; the heavy chain variable region comprises SEQ ID NO:1 The heavy chain CDR1, the heavy chain CDR2 shown in SEQ ID NO:2 and the heavy chain CDR3 shown in SEQ ID NO:3; the light chain variable region includes the light chain CDR1 shown in SEQ ID NO:4, SEQ ID NO:4 Light chain CDR2 shown in ID NO:5 and light chain CDR3 shown in SEQ ID NO:6. The anti-TIGIT monoclonal antibody of the invention has strong specific recognition and binding ability to the antigen TIGIT, can effectively block the combination of TIGIT and its ligand CD155, and has broad application prospects.

The invention relates to a specific polypeptide targeting and binding to lymphoid cancer cell lines and its application, which belongs to the field of biomedicine; the invention is based on in vitro phage display technology, and the specific polypeptide TUZG12 capable of targeting and binding to lymphoid cancer cell lines is obtained by panning in vitro In vitro cell uptake and distribution experiments prove that the polypeptide has targeted binding activity to lymphoma cell lines; the present invention also shows through in vitro cell activity experiments that pro-apoptotic peptide DKK coupled with TUZG12 polypeptide can improve to a certain extent The inhibitory effect of DKK on the proliferation activity of lymphoma cells; the polypeptide screened by the present invention has good targeting binding activity to multiple lymphoma cell lines, and can improve the killing effect of cytotoxic polypeptides on target tumor cells. It has important application value in diagnosis and treatment.

The invention relates to a hybridoma cell strain and a secreted monoclonal antibody thereof; the antibody can be specifically combined with a human IgM, and can be used for in vitro detection of the human IgM, and particularly suitable for early diagnosis of measles virus infection. The invention further relates to a kit comprising the hybridoma cell strain or the monoclonal antibody.

The invention relates to a hybridoma cell strain and a secreted monoclonal antibody thereof; the antibody can be specifically combined with a human IgM, and can be used for in vitro detection of the human IgM, and particularly suitable for early diagnosis of rubella virus infection. The invention further relates to a kit comprising the hybridoma cell strain or the monoclonal antibody.

The invention relates to an anti-cryptococcus capsular polysaccharide hybridoma cell line and the anti-cryptococcus capsular polysaccharide monoclonal antibody secreted therein, the antibody can specifically bind to the cryptococcal capsular polysaccharide, and can be used for in vitro detection of cryptococcal infection , its antibody titer is as high as more than one million, has excellent affinity, and has good specific binding ability; the detection limit of the colloidal gold-labeled immunodiagnostic reagent developed with this antibody as a raw material is 0.5ng / ml, in terms of sensitivity, Specificity, stability, all aspects of the antibody have better performance.

The invention relates to improvement of radiopharmaceutical yield and application of the radiopharmaceutical yield to the field of nuclear medicine and imaging, in particular to a medical radioisotope labeled P2X7 receptor targeting probe precursor, a targeting probe thereof and application of the targeting probe to diagnosis of neurodegenerative diseases. The structural formulas of the targeting probe are shown as a formula (III) and a formula (IV), wherein R4 and R6 are any one of a hydrogen atom, < 18 > FCH2CH2-and < 18 > FCH2CH2CH2-; r5 is any one of a fluorine atom, a chlorine atom, a bromine atom, an iodine atom and < 18 > F; x is any one of halogen atoms.

The present invention relates to a specific polypeptide targeting and binding to lymphoma cells and its application, belonging to the field of biomedicine; the amino acid sequence of the polypeptide D-REVTUZG12 is: RMLSGHGANPHM; the polypeptide D-REVTUZG12 is composed of D-type amino acids; The invention proves that the D-type reverse sequence polypeptide D-REVTUZG12 has targeted binding activity to four lymphoma cell lines Jeko-1, P815, Raji and Su-4 through in vitro cell uptake and distribution experiments, but it has no effect on Romas and Granta-519 Lymphoma cell lines and human normal lymphocytes have no target binding activity; the polypeptide involved in the present invention has good target binding activity to multiple lymphoma cell lines, and has clinical significance in the diagnosis and targeted therapy of lymphoma. important application prospects.

The invention relates to a hybridoma cell strain and a monoclonal antibody secreted by the hybridoma cell strain. The antibody can be specifically bound with human IgM, and can be used for in-vitro detection of the human IgM, and especially suitable for the early diagnosis of toxoplasma infection. The invention further relates to a kit containing the hybridoma cell strains or the monoclonal antibodies.

The invention relates to a hybridoma cell strain and a monoclonal antibody secreted by the hybridoma cell strain. The antibody can be specifically bound with human IgM, and can be used for in-vitro detection of the human IgM, and especially suitable for the early diagnosis of cytomegalovirus infection. The invention further relates to a kit containing the hybridoma cell strains or the monoclonal antibodies.

The invention relates to a hybridoma cell strain and a monoclonal antibody secreted by the hybridoma cell strain. The antibody can realize the specific combination with the human IgM, can be used forhuman IgM in-vitro detection, and is particularly suitable for being used for early diagnosis of hepatitis B virus. The invention also comprises a kit comprising the hybridoma cell strain or the monoclonal antibody.

The invention relates to a hybridoma cell strain and a monoclonal antibody secreted by the hybridoma cell strain. The antibody can achieve specific binding to human IgM and is applicable to in vitro detection of human IgM; and the antibody is especially suitable for early diagnosis of hepatitis a virus infection. The invention also relates to a kit comprising the hybridoma cell strain or the monoclonal antibody.